This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Infectious disease				
Ebola	Ebola glycoprotein GP1	Studies in primates suggest rabies (RABV)-based vaccine vectors expressing GP1 could be used to prevent Ebola infection. In macaques immunized with replication-competent, replication-deficient or inactivated RABV-GP1 vaccines, neutralizing antibodies against both GP1 and RABV glycoproteins were detected. In immunized macaques challenged with Ebola virus, the replication-competent vaccine protected 100% of the primates, whereas the replication-deficient and inactivated vaccines protected about 50% of the primates. Next steps could include optimizing a prime-boost vaccine strategy. *SciBX* 6(26); doi:10.1038/scibx.2013.657 Published online July 11, 2013	Patented; available for licensing from the NIH Office of Acquisition Management and Policy **Contact:** Peter Soukas, National Institutes of Health, Bethesda, Md. e-mail: soukasp@od.nih.gov	Blaney, J.E. *et al. PLoS Pathog.*; published online May 30, 2013; doi:10.1371/journal.ppat.1003389 **Contact:** Matthias J. Schnell, Thomas Jefferson University, Philadelphia, Pa. e-mail: matthias.schnell@jefferson.edu